<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of resectable endometrial carcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of resectable endometrial carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of resectable endometrial carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven C Plaxe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arno J Mundt, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H495849057"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer of the endometrium is the most common gynecologic malignancy in resource-abundant countries and the second most common in resource-limited countries (where cervical cancer is more common). Endometrioid carcinoma is the most common histologic type of endometrial carcinoma and of uterine malignancy overall. Endometrioid tumors tend to have a favorable prognosis and typically present at an early stage with abnormal uterine bleeding. Other histologic types of endometrial carcinoma (eg, serous, clear cell) as well as other types of uterine cancer are associated with a poor prognosis.</p><p>An overview of resectable endometrial carcinoma will be presented here. Related topics are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant therapy: (See  <a class="medical medical_review" href="/z/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other types of uterine cancer: (See  <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">"Endometrial carcinoma: Serous and clear cell histologies"</a> and  <a class="medical medical_review" href="/z/d/html/3211.html" rel="external">"Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"</a>.)</p><p></p><p class="headingAnchor" id="H4678240"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the United States, endometrial cancer develops in approximately 3 percent of, and is the fourth most common cancer among, females [<a href="#rid1">1-3</a>]. The incidence peaks between ages 60 and 70 years, but 2 to 5 percent of cases occur before age 40 years. Patients under age 50 who develop endometrial cancer are often at risk because of chronic anovulation and/or obesity. (See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a> and <a class="local">'Risk factors'</a> below.)</p><p class="headingAnchor" id="H4678842"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Among endometrial carcinomas, there are two histologic categories, which differ in incidence, responsiveness to hormonal therapy, and clinical behavior [<a href="#rid4">4,5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive histologies include grade 3 endometrioid tumors as well as tumors of nonendometrioid histology: serous, clear cell, and carcinosarcoma. Mixed, undifferentiated, mesonephric-like, and gastrointestinal-type mucinous carcinomas are also included into this group but are less common. This category is termed "aggressive" in the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system [<a href="#rid5">5</a>], and largely overlaps with type II tumors in older classification systems. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Traditional classification system'</a>.)</p><p></p><p class="bulletIndent1">These tumors represent a heterogenous group of tumors with some (eg, not estrogen sensitive, not associated with obesity, occur in the presence of an atrophic endometrium) having a poor prognosis and increased rates of recurrence. (See  <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">"Endometrial carcinoma: Serous and clear cell histologies"</a> and  <a class="medical medical_review" href="/z/d/html/3211.html" rel="external">"Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other cancers represent less aggressive histologies and include tumors of endometrioid histology that are grade 1 or 2. These comprise the majority (approximately 80 percent) of endometrial carcinomas. Nongastrointestinal type mucinous tumors (rare) are also included in this group. This category is termed "nonaggressive" in the 2023 FIGO staging system [<a href="#rid5">5</a>], and largely overlaps with type I tumors in older classification systems. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Traditional classification system'</a>.)</p><p></p><p class="bulletIndent1">These tumors typically have a favorable prognosis, are estrogen-induced and responsive to progestins, and may be preceded by an intraepithelial neoplasm (atypical and/or complex endometrial hyperplasia). Although these histologies are considered nonaggressive, they can still recur and be associated with a poor prognosis.</p><p></p><p class="bulletIndent1">The histology and pathogenesis of both types of endometrial carcinoma, including the role of molecular profiling to help inform prognosis and treatment decisions, are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification"</a>.)</p><p></p><p class="headingAnchor" id="H25012880"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The main risk factor for endometrioid endometrial carcinoma is an excess of endogenous (obesity) or exogenous estrogen without adequate opposition by a progestin (eg, postmenopausal estrogen therapy without a progestin). Patients often have a thickened endometrial stripe on pelvic ultrasound. Other risk factors include <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy, nulliparity, diabetes mellitus, and hypertension, as well as genetic risk factors, such as Lynch syndrome  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Risk factors'</a>.)</p><p>By contrast, patients with aggressive endometrial carcinomas tend to be older and have a lower body mass index; Black patients are also more likely than White patients to have aggressive tumors. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">"Endometrial carcinoma: Serous and clear cell histologies"</a>.)</p><p class="headingAnchor" id="H766015"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Endometrial carcinoma is a histologic diagnosis made based upon the results of evaluation of an endometrial biopsy, endometrial curettage, or hysterectomy specimen. (See  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1831948314"><span class="h1">STAGING AND SURGICAL TREATMENT</span></p><p class="headingAnchor" id="H2290076756"><span class="h2">Surgical staging for most patients</span><span class="headingEndMark"> — </span>Endometrial carcinoma is surgically staged according to the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 3</a>) [<a href="#rid5">5</a>]. This staging system includes histological type, tumor pattern, and molecular classification (if performed). This topic will utilize the 2023 FIGO staging system except when describing studies that used older staging systems.</p><p>Total extrafascial hysterectomy with bilateral salpingo-oophorectomy is standard for endometrial carcinoma [<a href="#rid5">5,6</a>]. Cytoreduction often is performed when metastases are evident. Surgery is typically performed via a minimally invasive route (robotic assisted or conventional laparoscopy). Additional routes (ie, laparotomy, vaginal) are individualized based on patient- and tumor-specific factors. The approach to lymph node evaluation in patients with endometrial carcinoma is a subject of debate, with options including pelvic-aortic lymph node dissection and sentinel lymph node biopsy, among others. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p>Surgery alone is usually curative for patients who are at a low risk of disease persistence or recurrence. Patients with intermediate- or high-risk disease may benefit from adjuvant therapy. (See <a class="local">'Role of adjuvant therapy'</a> below.)</p><p class="headingAnchor" id="H1982110093"><span class="h2">Fertility-preserving treatment in selected patients</span><span class="headingEndMark"> — </span>Patients with nonaggressive endometrial carcinomas who desire future childbearing may be candidates for treatment with progestin therapy (eg, <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a>). A thorough evaluation (with dilation and curettage, imaging studies) prior to medical therapy is necessary to try to confirm that the lesion is confined to the endometrium and is grade 1 or 2. However, patients who were presumed to have low-risk disease may ultimately have high-risk features at the time of hysterectomy [<a href="#rid7">7</a>].</p><p>Fertility preservation for patients with endometrial carcinoma is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer", section on 'Fertility preservation as alternative in selected patients'</a> and  <a class="medical medical_review" href="/z/d/html/101430.html" rel="external">"Fertility preservation in patients with endometrial carcinoma"</a>.)</p><p class="headingAnchor" id="H1047110"><span class="h1">ROLE OF ADJUVANT THERAPY</span><span class="headingEndMark"> — </span>For patients with newly diagnosed endometrial cancer who have undergone surgical treatment, risk stratification and approach to adjuvant therapy is discussed in the following sections and detailed in the algorithm  (<a class="graphic graphic_algorithm graphicRef143089" href="/z/d/graphic/143089.html" rel="external">algorithm 1</a>). Molecular factors, if obtained, may also help with risk stratification. This is discussed in detail below. (See <a class="local">'Molecular factors'</a> below.)</p><p class="headingAnchor" id="H1573783477"><span class="h2">Low-risk disease</span><span class="headingEndMark"> — </span>Low-risk endometrial cancer is defined as having <strong>all</strong> the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer that is endometrioid or nongastrointestinal mucinous type, <strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic grade 1 or 2, <strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited to the endometrium, or invading less than one-half of the myometrium, with no lymphovascular space invasion.</p><p></p><p>The overall probability of recurrence in these groups is very low following surgical treatment alone and adjuvant treatment is typically <strong>not</strong> indicated. (See  <a class="medical medical_review" href="/z/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer"</a>.)</p><p class="headingAnchor" id="H2427070973"><span class="h2">Intermediate-risk disease</span><span class="headingEndMark"> — </span>Intermediate-risk endometrial cancer is defined as disease that has the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer that is endometrioid or nongastrointestinal mucinous type and is <strong>any </strong>of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic grade 1 or 2 and invading less than one-half of the myometrium, with lymphovascular invasion; <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic grade 1 or 2 and invading more than one-half of the myometrium or demonstrating occult cervical stromal invasion; <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic grade 3 cancer and invading less than one-half of the myometrium. Note that we consider grade 3 endometrioid carcinoma that invades more than one-half of the myometrium to be high risk. (See  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers", section on 'Deeply invasive grade 3 endometrioid carcinoma'</a>.)</p><p></p><p>Among intermediate-risk cancers, some are classified as low-intermediate and others are classified as high-intermediate risk. Patients with low-intermediate risk endometrial cancer are typically not treated with adjuvant therapy. By contrast, patients with high-intermediate-risk endometrial cancer may benefit from postoperative radiation therapy (RT), administered via vaginal brachytherapy, for optimal local control (although no survival benefit has been demonstrated). Some clinicians may offer adjuvant chemotherapy (with or without RT) to patients with high-intermediate-risk endometrial cancer. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a>.)</p><p class="headingAnchor" id="H2112391658"><span class="h2">High-risk disease</span><span class="headingEndMark"> — </span>High-risk endometrial cancer includes patients with <strong>any</strong> of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Serous carcinoma, clear cell carcinoma, or carcinosarcoma (any stage), <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3, deeply invasive endometrioid carcinoma, <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage III or IV endometrial cancer  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 2</a>), any histology.</p><p></p><p>Patients with high-risk endometrial cancer have a poor prognosis and should be offered adjuvant chemotherapy. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p class="headingAnchor" id="H1160576732"><span class="h1">PROGNOSTIC FACTORS</span></p><p class="headingAnchor" id="H532462113"><span class="h2">Stage and histology</span><span class="headingEndMark"> — </span>The prognosis of endometrial carcinoma is determined primarily by disease stage and histology (including both grade and histologic subtype)  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 3</a>). Fortunately, most patients with endometrial carcinoma have a favorable prognosis since the majority of patients have endometrioid histology and present with early-stage disease.</p><p>In general, the rate of five-year survival for localized disease is approximately 95 percent, for regional disease it is 70 percent, and for distant disease it is 18 percent  (<a class="graphic graphic_figure graphicRef141351" href="/z/d/graphic/141351.html" rel="external">figure 1</a>) [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H762806923"><span class="h2">Lymphovascular space invasion</span><span class="headingEndMark"> — </span>Presence of lymphovascular space invasion (LVSI) is an independent risk factor for lymph node metastasis and disease recurrence [<a href="#rid9">9-12</a>]. This affects both disease classification and choice of adjuvant therapy. (See <a class="local">'Intermediate-risk disease'</a> above and  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a>.)</p><p>In a retrospective, multicenter study including over 1250 patients with endometrial cancer, distant recurrences were more frequent in patients with diffuse compared with focal or no LVSI (25, 15, and 7 percent, respectively) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1222789224"><span class="h2">Molecular factors</span><span class="headingEndMark"> — </span>Molecular factors that affect prognosis include mutations involving DNA polymerase epsilon (<em>POLE</em>) mutated subtype (<em>POLE</em>mut), mismatch repair deficient (dMMR), no specific molecular profile (NSMP), p53 abnormal (p53abn), and human epidermal growth factor receptor 2 (<em>HER2</em>). (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Integration of molecular subtypes'</a>.)</p><p>Although there are differences in access to molecular testing across centers, if obtained, such molecular factors can be used to up-stage or down-stage early endometrial carcinomas and may help inform prognosis [<a href="#rid5">5,14-16</a>]. As examples, patients with <em>POLE</em>mut tumors appear to have excellent disease-free survival, while patients with p53abn tumors appear to experience worse outcomes. Moreover, a retrospective analysis of 880 patients with early endometrial cancer enrolled in the Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC-1 and PORTEC-2) trials suggests that molecular factors may predict response to treatment [<a href="#rid14">14</a>]. In this analysis, there were no locoregional recurrences in <em>POLE</em>mut endometrial cancer regardless of whether adjuvant radiotherapy was administered. Similarly, in dMMR endometrial cancer, radiation (either vaginal brachytherapy [VBT] or external beam radiation therapy [EBRT]) was not associated with improvements in locoregional recurrence-free survival. However, in p53abn endometrial cancer, EBRT was associated with better locoregional recurrence-free survival at five years (97 percent), compared with either VBT (64 percent) and no adjuvant therapy (72 percent). Among patients with NSMP, locoregional control was better with either EBRT (98 percent) or VBT (96 percent) compared with no adjuvant treatment (88 percent). Importantly, ongoing trials will inform whether such molecular classification systems are truly prognostic and/or can effectively define treatment strategies [<a href="#rid17">17</a>]. The PORTEC-1 and PORTEC-2 trials are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p>Molecular factors are also discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Integration of molecular subtypes'</a>.)</p><p class="headingAnchor" id="H1147710442"><span class="h2">Other factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older age</strong> – Older age has been associated with higher rates of clinical failure and worse survival in several [<a href="#rid18">18-24</a>] (but not all [<a href="#rid25">25</a>]) studies. The association between age and prognosis can be illustrated by data from the Gynecologic Oncology Group protocol 33, in which five-year relative survival rates for patients with clinical stage I and II endometrial cancer stratified by age were as follows [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≤40 years old – 96 percent</p><p class="bulletIndent2"><span class="glyph">•</span>41 to 50 years old – 94 percent</p><p class="bulletIndent2"><span class="glyph">•</span>51 to 60 years old – 87 percent</p><p class="bulletIndent2"><span class="glyph">•</span>61 to 70 years old – 78 percent</p><p class="bulletIndent2"><span class="glyph">•</span>71 to 80 years old – 71 percent</p><p class="bulletIndent2"><span class="glyph">•</span>≥80 years old – 54 percent</p><p></p><p class="bulletIndent1">Whether age represents an independent prognostic factor is controversial. Patients over the age of 65 have more frequent deep myometrial invasion, high tumor grade, and advanced tumor stage [<a href="#rid19">19,25-28</a>]. Furthermore, less aggressive therapy could also account for some of the poor outcomes seen in older patients [<a href="#rid25">25,27,28</a>]. As noted elsewhere, age is used to categorize patients with intermediate-risk disease into either a high- or low-intermediate-risk group, which may influence treatment decisions. However, even when treated in uniform fashion, older patients seem to have higher recurrence rates and inferior survival compared with their younger counterparts. (See  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer", section on 'Classification'</a>.)</p><p></p><p>Other factors that may inform prognosis but are not typically used in treatment decisions include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower uterine segment involvement</strong> – Patients with otherwise low-risk disease who have involvement of the lower uterine segment may be at a greater risk for nodal involvement. However, it is not clear if involvement of the lower uterine segment represents an independent risk factor for survival. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer", section on 'Patients with lower uterine segment involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive peritoneal cytology</strong> – Approximately 11 percent of patients undergoing surgical staging have positive peritoneal cytology, most commonly in the setting of advanced (extrauterine) disease [<a href="#rid29">29,30</a>]. However, positive peritoneal cytology is not considered in the staging system for endometrial carcinoma  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 3</a>) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">The prognostic significance of isolated positive peritoneal washings in the absence of extrauterine spread remains controversial. In a 2012 analysis of 14,704 patients identified from the Surveillance, Epidemiology, and End Results (SEER) registry, positive peritoneal cytology was an independent predictor of mortality, regardless of histologic subtype, among patients with early-stage (stage I to II) endometrial carcinoma [<a href="#rid31">31</a>]. A previous systematic review, however, found that the prognosis associated with a positive peritoneal cytology varied according to the presence of other factors [<a href="#rid32">32</a>]. Patients with positive peritoneal cytology, but otherwise low-risk disease had lower rates of recurrence compared with other patients with positive peritoneal cytology (4.1 versus 32 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race</strong> – Race also factors into prognosis. Black patients have a consistently poorer outcome than White patients [<a href="#rid3">3</a>], an effect that is incompletely explained by imbalances in race-based biases, socioeconomic factors, and disparities in access to care [<a href="#rid33">33-41</a>]. Some of the racial disparity in survival has been attributed to a lower incidence of good-prognosis (low-grade endometrioid) cancers in Black patients and a higher incidence of high-risk (grade 3 and nonendometrioid) tumors [<a href="#rid42">42,43</a>]. However, an alternative explanation for the worse survival is provided by data suggesting that at least in uterine serous cancers, Black patients have a higher frequency of overexpressed or amplified human epidermal growth factor receptor 2 [<a href="#rid44">44-46</a>].</p><p></p><p class="bulletIndent1">In contrast to Black patients, Asian patients appear to have a better survival relative to other populations [<a href="#rid3">3</a>], an effect that is attributed at least in part to younger age at diagnosis. In data from SEER of the National Cancer Institute, 1 in 50 Asian patients with uterine cancer was diagnosed before age 35 as compared with 1 in 150 White patients [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H11157097"><span class="h1">POST-TREATMENT CONSIDERATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – The post-treatment follow-up of patients with endometrial cancer consists mainly of monitoring for symptoms and physical examinations. Routine use of laboratories (serum cancer antigen [CA] 125) and/or imaging is limited. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17006.html" rel="external">"Overview of approach to endometrial cancer survivors", section on 'Follow-up post-treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent disease</strong> – Recurrent endometrial cancer presents variably, including disease localized to the vagina or pelvis, or as metastatic disease. Although the prognosis for the vast majority is poor, carefully selected patients with locoregional recurrence can be cured with an aggressive locoregional approach. (See  <a class="medical medical_review" href="/z/d/html/3186.html" rel="external">"Management of locoregional recurrence of endometrial cancer"</a>.)</p><p></p><p class="bulletIndent1">Management of metastatic recurrence is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/126055.html" rel="external">"Initial treatment of metastatic endometrial cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Specific issues for endometrial cancer survivors (eg, postmenopausal hormone therapy, sexual health) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17006.html" rel="external">"Overview of approach to endometrial cancer survivors"</a>.)</p><p></p><p class="headingAnchor" id="H2036457513"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H11157151"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/866.html" rel="external">"Patient education: Endometrial cancer diagnosis, staging, and surgical treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/871.html" rel="external">"Patient education: Endometrial cancer treatment after surgery (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11157046"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Uterine cancer is the most common gynecologic malignancy in resource-abundant countries and is the second most common in resource-limited countries (where cervical cancer is more common). In the United States, endometrial cancer is the fourth most common cancer in females. The incidence peaks between ages 60 and 70 years, but 2 to 5 percent of cases occur before age 40 years. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive histologies include grade 3 endometrioid carcinoma, carcinosarcoma, serous, clear cell, and gastrointestinal mucinous type tumors. These represent a heterogenous group of tumors with some (eg, not estrogen sensitive, not associated with obesity, occur in the presence of an atrophic endometrium) having a poor prognosis and increased rates of recurrence. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other cancers represent less aggressive histologies and include grade 1 and 2 endometrioid cancers and nongastrointestinal mucinous cancers. These cancers typically have a favorable prognosis, are estrogen-induced and responsive to progestins, and may be preceded by an intraepithelial neoplasm. Although these histologies are considered "nonaggressive," they too can recur and be associated with a poor prognosis. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The main risk factor for endometrioid endometrial carcinoma is an excess of endogenous or exogenous estrogen without adequate opposition by a progestin (eg, postmenopausal estrogen therapy without a progestin). Other risk factors include <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy, obesity, nulliparity, diabetes mellitus, and hypertension and genetic factors, including Lynch syndrome  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 1</a>). (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1">By contrast, patients with aggressive endometrial carcinomas tend to be older and have a lower body mass index; Black patients are also more likely than White patients to have aggressive tumors. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Endometrial carcinoma is a histologic diagnosis made based upon the results of evaluation of an endometrial biopsy, endometrial curettage, or hysterectomy specimen. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – Endometrial carcinoma is surgically staged according to the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system  (<a class="graphic graphic_table graphicRef141918" href="/z/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/z/d/graphic/141963.html" rel="external">table 3</a>). (See <a class="local">'Staging and surgical treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Surgery alone is usually curative for patients who are at a low risk of disease persistence or recurrence. Patients with intermediate- or high-risk disease may benefit from adjuvant therapy  (<a class="graphic graphic_algorithm graphicRef143089" href="/z/d/graphic/143089.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a> and  <a class="medical medical_review" href="/z/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients with endometrial carcinoma have a favorable prognosis since the majority of patients have endometrioid histology and present with early-stage disease  (<a class="graphic graphic_figure graphicRef141351" href="/z/d/graphic/141351.html" rel="external">figure 1</a>). (See <a class="local">'Stage and histology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors</strong> – Beyond stage, tumor histology, lymphatic and vascular space involvement, and molecular factors, other factors (lower uterine segment involvement, older age, and Black race) may also be used to inform prognosis. (See <a class="local">'Prognostic factors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Cancer stat facts: Uterine cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/corp.html.</li><li class="breakAll">American Cancer Society. Cancer Facts &amp; Figures 2019. Atlanta: American Cancer Society; 2019 http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.</li><li><a class="nounderline abstract_t">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12.</a></li><li><a class="nounderline abstract_t">Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010; 21:1851.</a></li><li><a class="nounderline abstract_t">Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162:383.</a></li><li><a class="nounderline abstract_t">Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105:103.</a></li><li><a class="nounderline abstract_t">Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:804.</a></li><li class="breakAll">Cancer Stat Facts: Uterine Cancer. National Cancer Institutes. Available at: https://seer.cancer.gov/statfacts/html/corp.html (Accessed on April 25, 2023).</li><li><a class="nounderline abstract_t">Bosse T, Peters EE, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015; 51:1742.</a></li><li><a class="nounderline abstract_t">Ørtoft G, Lausten-Thomsen L, Høgdall C, et al. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study. J Gynecol Oncol 2019; 30:e84.</a></li><li><a class="nounderline abstract_t">dos Reis R, Burzawa JK, Tsunoda AT, et al. Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer 2015; 25:1292.</a></li><li><a class="nounderline abstract_t">Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55.</a></li><li><a class="nounderline abstract_t">Restaino S, Tortorella L, Dinoi G, et al. Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications. Eur J Cancer 2021; 142:29.</a></li><li><a class="nounderline abstract_t">Horeweg N, Nout RA, Jürgenliemk-Schulz IM, et al. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer. J Clin Oncol 2023; 41:4369.</a></li><li><a class="nounderline abstract_t">Schwameis R, Fanfani F, Ebner C, et al. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres. Eur J Cancer 2023; 193:113317.</a></li><li><a class="nounderline abstract_t">Matsuo K, Klar M, Song BB, et al. Validation of the 2023 FIGO staging schema for advanced endometrial cancer. Eur J Cancer 2023; 193:113316.</a></li><li><a class="nounderline abstract_t">RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer 2022; 33:109.</a></li><li><a class="nounderline abstract_t">Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 2010; 116:399.</a></li><li><a class="nounderline abstract_t">Jolly S, Vargas CE, Kumar T, et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol 2006; 103:87.</a></li><li><a class="nounderline abstract_t">Alektiar KM, Venkatraman E, Abu-Rustum N, Barakat RR. Is endometrial carcinoma intrinsically more aggressive in elderly patients? Cancer 2003; 98:2368.</a></li><li><a class="nounderline abstract_t">Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355:1404.</a></li><li><a class="nounderline abstract_t">Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.</a></li><li><a class="nounderline abstract_t">Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 2007; 109:655.</a></li><li><a class="nounderline abstract_t">Ghanem AI, Bhatnagar A, Elshaikh M, et al. Recurrence Risk Stratification for Women With FIGO Stage I Uterine Endometrioid Carcinoma Who Underwent Surgical Lymph Node Evaluation. Am J Clin Oncol 2023; 46:537.</a></li><li><a class="nounderline abstract_t">Mundt AJ, Waggoner S, Yamada D, et al. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol 2000; 79:79.</a></li><li><a class="nounderline abstract_t">Grigsby PW, Perez CA, Kuten A, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992; 22:905.</a></li><li><a class="nounderline abstract_t">Goodwin JS, Samet JM, Key CR, et al. Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 1986; 34:20.</a></li><li><a class="nounderline abstract_t">Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255:3385.</a></li><li><a class="nounderline abstract_t">Shah C, Johnson EB, Everett E, et al. Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer. Gynecol Oncol 2005; 99:564.</a></li><li><a class="nounderline abstract_t">Matsuo K, Matsuzaki S, Roman LD, et al. Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. Am J Obstet Gynecol 2021; 224:319.</a></li><li><a class="nounderline abstract_t">Garg G, Gao F, Wright JD, et al. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol 2013; 128:77.</a></li><li><a class="nounderline abstract_t">Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol 2009; 115:18.</a></li><li><a class="nounderline abstract_t">Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714.</a></li><li><a class="nounderline abstract_t">Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10:31.</a></li><li><a class="nounderline abstract_t">Hicks ML, Phillips JL, Parham G, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 1998; 83:2629.</a></li><li><a class="nounderline abstract_t">Connell PP, Rotmensch J, Waggoner SE, Mundt AJ. Race and clinical outcome in endometrial carcinoma. Obstet Gynecol 1999; 94:713.</a></li><li><a class="nounderline abstract_t">Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 2006; 107:2197.</a></li><li><a class="nounderline abstract_t">Clifford SL, Kaminetsky CP, Cirisano FD, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol 1997; 176:S229.</a></li><li><a class="nounderline abstract_t">Farley JH, Tian C, Rose GS, et al. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer 2010; 116:355.</a></li><li><a class="nounderline abstract_t">Kucera CW, Tian C, Tarney CM, et al. Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer. JAMA Netw Open 2023; 6:e238437.</a></li><li><a class="nounderline abstract_t">Doll KM. Endometrial Cancer and Reproductive Justice. Obstet Gynecol 2023; 142:477.</a></li><li><a class="nounderline abstract_t">Plaxe SC, Saltzstein SL. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol 1997; 65:8.</a></li><li><a class="nounderline abstract_t">Schimp VL, Ali-Fehmi R, Solomon LA, et al. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? Gynecol Oncol 2006; 102:440.</a></li><li><a class="nounderline abstract_t">Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991; 164:15.</a></li><li><a class="nounderline abstract_t">Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47:179.</a></li><li><a class="nounderline abstract_t">Somasegar S, Bashi A, Lang SM, et al. Trends in Uterine Cancer Mortality in the United States: A 50-Year Population-Based Analysis. Obstet Gynecol 2023; 142:978.</a></li><li><a class="nounderline abstract_t">Zhang MM, Cheung MK, Osann K, et al. Improved survival of Asians with corpus cancer compared with whites: an analysis of underlying factors. Obstet Gynecol 2006; 107:329.</a></li></ol></div><div id="topicVersionRevision">Topic 16917 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://seer.cancer.gov/statfacts/html/corp.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer stat facts: Uterine cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/corp.html.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Cancer Society. Cancer Facts &amp; Figures 2019. Atlanta: American Cancer Society; 2019 http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38230766" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancer statistics, 2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628804" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Factors associated with Type I and Type II endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37337978" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : FIGO staging of endometrial cancer: 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19367689" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16400640" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16400640" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26049688" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31328462" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26067863" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1989916" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33217679" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37487144" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37748967" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37741790" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Validation of the 2023 FIGO staging schema for advanced endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600534" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20022094" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545441" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14635071" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is endometrial carcinoma intrinsically more aggressive in elderly patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791524" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984936" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329517" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognostic factors for uterine cancer in reproductive-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37679878" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recurrence Risk Stratification for Women With FIGO Stage I Uterine Endometrioid Carcinoma Who Underwent Surgical Lymph Node Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11006036" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Age as a prognostic factor for recurrence in patients with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555983" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3941240" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Stage at diagnosis of cancer varies with the age of the patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3712698" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Choice of cancer therapy varies with age of patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246402" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33127431" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032094" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632708" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740298" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8115784" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874471" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The National Cancer Data Base report on endometrial carcinoma in African-American women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10546716" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Race and clinical outcome in endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17001661" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215213" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924790" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37067801" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37590979" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Endometrial Cancer and Reproductive Justice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9103384" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of ethnicity on the incidence of high-risk endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510175" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1670908" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361478" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : HER-2/neu expression: a major prognostic factor in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37678887" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Trends in Uterine Cancer Mortality in the United States: A 50-Year Population-Based Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449120" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improved survival of Asians with corpus cancer compared with whites: an analysis of underlying factors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
